ALCAM and myeloid sarcoma: Moreover, blocking CD6 expression restricts the transmigration of CD4+ lymphocytes and monocytes across BBB endothelium and reduces the severity of EAE, suggesting that targeting ALCAM could be a potential therapeutic strategy for MS by limiting immune cell infiltration into the central nervous system [20].